Corvus Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CRVS Nasdaq 2834 www.corvuspharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Faces Key Soquelitinib Data And Possible M&A Interest - Jun 14th, 2026 4:09 pm
Is Corvus Pharmaceuticals, Inc. (CRVS) A Good Stock To Buy Now? - Jun 13th, 2026 9:53 am
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China - Jun 9th, 2026 5:30 am
Adams Street Partners Exits Its 223,000-Share Paymentus (PAY) Position for $5.9 Million - May 24th, 2026 7:42 am
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference - May 20th, 2026 2:01 pm
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase - May 17th, 2026 2:46 pm
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting - May 14th, 2026 5:00 am
Return To Losses And New Shelf Offering Might Change The Case For Investing In Corvus Pharmaceuticals (CRVS) - May 10th, 2026 3:08 am
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results - May 7th, 2026 2:01 pm
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors - Apr 23rd, 2026 5:30 am
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting - Apr 21st, 2026 5:30 am
Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi‑Year Share Price Gains - Mar 13th, 2026 2:08 pm
Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Mar 13th, 2026 6:30 am
Corvus (CRVS) Q4 2025 Earnings Call Transcript - Mar 12th, 2026 9:30 pm
Corvus Pharmaceuticals Inc (CRVS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... - Mar 12th, 2026 9:07 pm
Corvus Pharmaceuticals Q4 Earnings Call Highlights - Mar 12th, 2026 4:46 pm
Corvus: Q4 Earnings Snapshot - Mar 12th, 2026 2:08 pm
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Mar 12th, 2026 2:01 pm
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 - Mar 5th, 2026 2:01 pm
Corvus Pharmaceuticals Highlights Soquelitinib Pipeline, Eyes Phase II Atopic Dermatitis Trial in 2026 - Feb 27th, 2026 10:39 am